Active PI3K abrogates central tolerance in high-avidity autoreactive B cells.
Sarah A GreavesJacob N PetersonPamela J StrauchRaul M TorresRoberta PelandaPublished in: The Journal of experimental medicine (2019)
Autoreactive B cells that bind self-antigen with high avidity in the bone marrow undergo mechanisms of central tolerance that prevent their entry into the peripheral B cell population. These mechanisms are breached in many autoimmune patients, increasing their risk of B cell-mediated autoimmune diseases. Resolving the molecular pathways that can break central B cell tolerance could therefore provide avenues to diminish autoimmunity. Here, we show that B cell-intrinsic expression of a constitutively active form of PI3K-P110α by high-avidity autoreactive B cells of mice completely abrogates central B cell tolerance and further promotes these cells to escape from the bone marrow, differentiate in peripheral tissue, and undergo activation in response to self-antigen. Upon stimulation with T cell help factors, these B cells secrete antibodies in vitro but remain unable to secrete autoantibodies in vivo. Overall, our data demonstrate that activation of the PI3K pathway leads high-avidity autoreactive B cells to breach central, but not late, stages of peripheral tolerance.
Keyphrases
- bone marrow
- mesenchymal stem cells
- end stage renal disease
- poor prognosis
- multiple sclerosis
- induced apoptosis
- newly diagnosed
- chronic kidney disease
- systemic lupus erythematosus
- type diabetes
- electronic health record
- oxidative stress
- machine learning
- prognostic factors
- insulin resistance
- single molecule
- skeletal muscle
- cell proliferation
- endoplasmic reticulum stress